Shanghai Junshi Biosciences Co (HKSE:01877) EPS (Diluted) : HK$-1.27 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co EPS (Diluted)?

Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was HK$-0.32. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.27.

Shanghai Junshi Biosciences Co's EPS (Basic) for the three months ended in Mar. 2024 was HK$-0.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.27.

Shanghai Junshi Biosciences Co's EPS without NRI for the three months ended in Mar. 2024 was HK$-0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.23.

During the past 3 years, the average EPS without NRIGrowth Rate was -1.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Shanghai Junshi Biosciences Co's highest 3-Year average EPS without NRI Growth Rate was 5.10% per year. The lowest was -73.60% per year. And the median was -39.70% per year.

Shanghai Junshi Biosciences Co EPS (Diluted) Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co EPS (Diluted) Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.06

-2.40

-0.98

-2.90

-2.54

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial														-0.63	-0.50	-0.45	-	-0.32

Competitive Comparison of Shanghai Junshi Biosciences Co's EPS (Diluted)

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's PE Ratio falls into.

Shanghai Junshi Biosciences Co EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Shanghai Junshi Biosciences Co's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2495.592	-	0)	/	985.302
	=	-2.53

Shanghai Junshi Biosciences Co's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-307.455	-	0)	/	975.962
	=	-0.32

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.27

Shanghai Junshi Biosciences Co (HKSE:01877) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Shanghai Junshi Biosciences Co EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines